Mengxing Xue

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Qian Jiang, Xiao‐Jun Huang, Zi Chen et al. · Blood · 2020 · 25 citations

Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts

Mengxing Xue, Qinrong Wang, Li Huo et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2019 · 20 citations

Mixed-phenotype Acute Leukemia, Tki Era, Pathology +17

The Role of Interleukin-15 Polymorphisms in Adult Acute Lymphoblastic Leukemia

Dandan Lin, Chunliang Liu, Mengxing Xue et al. · PLoS ONE · 2010 · 16 citations · Full text

Low‐dose cytarabine and aclarubicin combined with granulocyte colony‐stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients

Shengli Xue, Hongxia Cui, Jing‐Ying Zou et al. · Hematological Oncology · 2013 · 15 citations

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant <i>BCR-ABL1 T315I</i>-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)

Qian Jiang, Dayu Shi, Zongru Li et al. · Blood · 2021 · 11 citations